Long term outcomes following achievement of clinically inactive disease in juvenile idiopathic arthritis: the importance of definition

Juvenile Idiopathic Arthritis

Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort

Arthritis Care Res (Hoboken).

Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, Rygg M, Toftedal P, Nielsen S, Fasth A, Berntson L, Nordal E, Herlin T, Nordic Study Group of Pediatric Rheumatology (NoSPeR)

doi: 10.1002/acr.23853.

Juvenile Idiopathic Arthritis

Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study

Rheumatology (Oxford).

Heiligenhaus A, Klotsche J, Tappeiner C, Sengler C, Niewerth M, Liedmann I, Hoeft S, Walscheid K, Lavric M, Foell D, Minden K

doi: 10.1093/rheumatology/key406.

Juvenile Idiopathic Arthritis

Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience

Rheumatology (Oxford).

Chhabra A, Robinson C, Houghton K, Cabral DA, Morishita K, Tucker LB, Petty RE, Larché M, Batthish M, Guzman J

doi: 10.1093/rheumatology/keaa118.

Juvenile Idiopathic Arthritis

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Ann Rheum Dis.

Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, Kasapcopur O, Schneider R, Anton J, Barash J, Berner R, Corona F, Cuttica R, Fouillet-Desjonqueres M, Fischbach M, Foster HE, Foell D, Radominski SC, Ramanan AV, Trauzeddel R, Unsal E, Levy J, Vritzali E, Martini A, Lovell DJ

doi: 10.1136/annrheumdis-2018-213150.

COMMENTED

Juvenile Idiopathic Arthritis

Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra

Rheumatology (Oxford).

Kearsley-Fleet L, Beresford MW, Davies R, De Cock D, Baildam E, Foster HE, Southwood TR, Thomson W, Hyrich KL

doi: 10.1093/rheumatology/key262.

Juvenile Idiopathic Arthritis

Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis: part 1-results of the Canadian model in the Nordic cohort

Arthritis Res Ther.

Rypdal V, Guzman J, Henrey A, Loughin T, Glerup M, Arnstad ED, Aalto K, Rygg M, Nielsen S, Herlin T, Fasth A, Berntson L, Rypdal M, Nordal E, ReACCh-Out and NoSPeR Investigators.

doi: 10.1186/s13075-019-2060-2.

Juvenile Idiopathic Arthritis

Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany

Arthritis Res Ther.

Heiligenhaus A, Klotsche J, Niewerth M, Horneff G, Ganser G, Haas JP, Minden K

doi: 10.1186/s13075-020-02166-3.

Juvenile Idiopathic Arthritis

Long-term Outcomes of Temporomandibular Joints in Juvenile Idiopathic Arthritis

J Rheumatol.

Glerup M, Stoustrup P, Hauge L, Rypdal V, Nordal E, Frid P, Arnstad ED, Rygg M, Thorarensen O, Ekelund M, Berntson L, Fasth A, Nilsson H, Peltoniemi S, Aalto K, Arte S, Toftedal P, Nielsen S, Kreiborg S, Herlin T, Pedersen TK

doi: 10.3899/jrheum.190231.

Juvenile Idiopathic Arthritis

Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis part 2: results of the Nordic model in the Canadian cohort

Arthritis Res Ther.

Henrey A, Rypdal V, Rypdal M, Loughin T, Nordal E, Guzman J, ReACCh-Out and NoSPeR Investigators.

doi: 10.1186/s13075-019-2091-8.

Related content

Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort

Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study

Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra

Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis: part 1-results of the Canadian model in the Nordic cohort

Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany

Long-term Outcomes of Temporomandibular Joints in Juvenile Idiopathic Arthritis

Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis part 2: results of the Nordic model in the Canadian cohort